CBD of Denver Inc. (CBDD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CBD of Denver Inc. (CBDD) trades at $0.00 with AI Score 51/100 (Grade B). CBD of Denver Inc. focuses on the development and commercialization of cannabidiol (CBD) products, including research, development, and distribution of premium hemp extract products. Market cap: $1.07M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CBDD: CBDD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDD against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CBDD: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →CBD of Denver Inc. (CBDD) Healthcare & Pipeline Overview
CBD of Denver Inc. is a cannabidiol (CBD) product company involved in the research, development, and distribution of premium hemp extract products. Operating as a subsidiary of Swiss Industry Ventures AG, the company focuses on commercializing CBD products within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for CBDD?
CBD of Denver Inc. presents a speculative investment opportunity within the rapidly evolving CBD market. The company's focus on premium hemp extract products and its position as a subsidiary of Swiss Industry Ventures AG could provide a competitive edge. However, the company's financial performance and market capitalization of $1.07M indicate significant risks. A gross margin of 27.1% suggests potential profitability challenges. The negative beta of -10.69 indicates an inverse correlation with the market, which could be a double-edged sword. Growth catalysts include potential expansion into new product lines and geographic markets. Investors should carefully evaluate the company's OTC status and associated risks before considering an investment.
Based on FMP financials and quantitative analysis
CBDD Key Highlights
- Market Cap of $1.07M reflects the company's small size and potential volatility.
- Gross Margin of 27.1% indicates the profitability of CBDD's core operations.
- Beta of -10.69 suggests an inverse correlation with the broader market.
- CBDD operates as a subsidiary of Swiss Industry Ventures AG.
- CBDD focuses on the development and commercialization of cannabidiol (CBD) products.
Who Are CBDD's Competitors?
CBDD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDD's Key Strengths?
- Focus on premium hemp extract products.
- Subsidiary of Swiss Industry Ventures AG.
- Established presence in the CBD market.
- Commitment to research and development.
What Are CBDD's Weaknesses?
- Small market capitalization.
- Limited financial resources.
- Dependence on the CBD market.
- OTC market listing.
What Could Drive CBDD Stock Higher?
- Potential expansion into new therapeutic areas.
- Geographic expansion into new markets.
- Development of innovative CBD products.
- Strategic partnerships and acquisitions.
- Focus on quality and compliance.
What Are the Key Risks for CBDD?
- Negative return on equity (-16.6%) — the business is not currently generating profit on shareholder capital.
- Intense competition in the CBD market.
- Evolving regulations and consumer preferences.
- Negative publicity or product recalls.
- Fluctuations in the price of hemp extract.
- Limited financial resources.
What Are the Growth Opportunities for CBDD?
- Expansion into New Therapeutic Areas: CBD of Denver Inc. has the opportunity to expand its product line into new therapeutic areas, such as pain management, anxiety relief, and sleep disorders. The market for CBD-based therapeutic products is growing rapidly, driven by increasing consumer awareness and scientific research. By developing and commercializing targeted CBD formulations, CBD of Denver Inc. can tap into this lucrative market segment and differentiate itself from competitors. This expansion could involve partnerships with healthcare providers and research institutions. The timeline for this growth opportunity is estimated at 2-3 years, with a potential market size of $5 billion.
- Geographic Expansion: CBD of Denver Inc. can pursue geographic expansion into new markets, both domestically and internationally. The global CBD market is highly fragmented, with significant growth potential in emerging markets. By establishing distribution partnerships and tailoring its product offerings to local preferences, CBD of Denver Inc. can expand its reach and increase its revenue. This expansion could involve entering into joint ventures or acquiring local CBD companies. The timeline for this growth opportunity is estimated at 3-5 years, with a potential market size of $10 billion.
- Development of Innovative CBD Products: CBD of Denver Inc. can invest in research and development to create innovative CBD products with enhanced efficacy and bioavailability. This could involve developing novel formulations, delivery systems, and extraction methods. By patenting its innovations and establishing a strong intellectual property portfolio, CBD of Denver Inc. can gain a competitive advantage and attract strategic partners. The timeline for this growth opportunity is estimated at 2-4 years, with a potential market size of $3 billion.
- Strategic Partnerships and Acquisitions: CBD of Denver Inc. can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with established healthcare companies, retailers, or distributors. By acquiring complementary businesses, CBD of Denver Inc. can gain access to new technologies, products, and distribution channels. The timeline for this growth opportunity is estimated at 1-3 years, with a potential market size of $2 billion.
- Focus on Quality and Compliance: CBD of Denver Inc. can differentiate itself by focusing on product quality and regulatory compliance. This involves implementing rigorous quality control measures, obtaining certifications, and adhering to all applicable regulations. By building a reputation for quality and compliance, CBD of Denver Inc. can gain the trust of consumers and healthcare providers. The timeline for this growth opportunity is ongoing, with a potential market size of $1 billion.
What Opportunities Does CBDD Have?
- Expansion into new therapeutic areas.
- Geographic expansion into new markets.
- Development of innovative CBD products.
- Strategic partnerships and acquisitions.
What Threats Does CBDD Face?
- Intense competition in the CBD market.
- Evolving regulations and consumer preferences.
- Potential for negative publicity or product recalls.
- Fluctuations in the price of hemp extract.
What Are CBDD's Competitive Advantages?
- Proprietary CBD formulations and extraction methods.
- Established distribution network.
- Strong brand reputation for quality and compliance.
- Strategic partnerships with key players in the healthcare and wellness industries.
What Does CBDD Do?
CBD of Denver Inc., formerly known as Verde Media Group, Inc., was rebranded in 2018 to focus on the burgeoning cannabidiol (CBD) market. The company is dedicated to the research, development, and commercialization of a range of CBD products. Its core business revolves around the creation and distribution of premium hemp extract products, catering to a growing demand for CBD-based solutions. Headquartered in Centennial, Colorado, CBD of Denver Inc. operates as a subsidiary of Swiss Industry Ventures AG, leveraging its parent company's resources and expertise. The company's evolution reflects the increasing acceptance and market potential of CBD in various applications, from wellness to potential therapeutic uses. CBD of Denver Inc. aims to establish itself as a key player in the CBD market by focusing on product quality, innovation, and strategic distribution partnerships. The company's commitment to research and development underscores its ambition to stay at the forefront of CBD advancements and capitalize on emerging opportunities within the healthcare and wellness sectors. CBD of Denver Inc. distributes its products through various channels, targeting both retail consumers and potential business-to-business partnerships.
What Products and Services Does CBDD Offer?
- Develops and commercializes cannabidiol (CBD) products.
- Engages in the research of hemp extract products.
- Distributes premium hemp extract products.
- Focuses on the wellness and potential therapeutic applications of CBD.
- Operates as a subsidiary of Swiss Industry Ventures AG.
- Aims to establish a strong presence in the CBD market.
How Does CBDD Make Money?
- Develops and formulates CBD products.
- Manufactures or outsources the production of CBD products.
- Distributes CBD products through various channels, including retail and online sales.
- Generates revenue from the sale of CBD products.
What Industry Does CBDD Operate In?
CBD of Denver Inc. operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing significant growth due to the increasing acceptance and legalization of cannabis and CBD products. The market is characterized by intense competition, with numerous companies vying for market share. The industry is also subject to evolving regulations and consumer preferences. CBD of Denver Inc.'s success depends on its ability to differentiate its products, navigate the regulatory landscape, and establish strong distribution channels. The global CBD market is projected to reach billions of dollars in the coming years, presenting both opportunities and challenges for companies like CBD of Denver Inc.
Who Are CBDD's Key Customers?
- Consumers seeking wellness and therapeutic benefits from CBD.
- Retailers and distributors of CBD products.
- Healthcare providers interested in CBD-based solutions.
- Businesses seeking to incorporate CBD into their products.
F-Score 4/9Financial Health
CBD of Denver Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Quarterly Financial Performance: CBD of Denver Inc.
Revenue for CBD of Denver Inc. came in at $557K during Q1 2025, a 35.6% contraction versus the preceding quarter. The company recorded a net loss of $15K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CBDD averaged $0.00 in diluted EPS.
CBDD Valuation & Market Position
With a $1.07M market cap, CBD of Denver Inc. sits in the micro-cap segment of the market. Relative to its peer group, CBDD's quantitative score of 51/100 is below the peer average of 66/100.
ROE -17%Key Financial Metrics
Return on equity for CBD of Denver Inc. stands at -16.6%, a gauge of how efficiently it converts shareholder capital into profit. CBDD trades at a trailing price-to-earnings ratio of 3.86, below the Healthcare sector average of ~23x. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 25.9%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
CBD of Denver Inc. operates in the Specialty Retail industry within the Consumer Cyclical sector. It is headquartered in Centennial, US. The company is led by CEO Syed Hussain I. Abidi. CBDD has traded publicly since 1996.
CBDD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on premium hemp extract products.
- Subsidiary of Swiss Industry Ventures AG.
- Established presence in the CBD market.
- Commitment to research and development.
Bear Case
- Small market capitalization.
- Limited financial resources.
- Dependence on the CBD market.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $557,116 | -$14,835 | $0.00 |
| Q4 2024 | $864,934 | $237,280 | $0.00 |
| Q3 2024 | $763,450 | -$96,988 | $0.00 |
| Q2 2024 | $1M | -$124,000 | $0.00 |
Based on FMP financials and quantitative analysis
CBDD Latest News
-
CBD of Denver, Inc. (CBDD) Advances Evaluation of AI-Driven Health & Wellness Acquisition Opportunity
newsfilecorp.com · Jun 30, 2026
-
CBD of Denver Announces Updated Corporate Website Reflecting Strategic Pivot into Artificial Intelligence
newsfilecorp.com · Jun 22, 2026
-
CBD of Denver Announces Strategic Exploration of Merger Candidates
feeds.newsfilecorp.com · Jun 11, 2026
-
CBD of Denver, Inc. Identifies Strategic Opportunities to Maximize Shareholder Value
newsfilecorp.com · May 12, 2026
CBDD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDD.
Price Targets
Wall Street price target analysis for CBDD.
CBDD MoonshotScore
What does this score mean?
The MoonshotScore rates CBDD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
CBD of Denver, Inc. (CBDD) Advances Evaluation of AI-Driven Health & Wellness Acquisition Opportunity
CBD of Denver Announces Updated Corporate Website Reflecting Strategic Pivot into Artificial Intelligence
CBD of Denver Announces Strategic Exploration of Merger Candidates
CBD of Denver, Inc. Identifies Strategic Opportunities to Maximize Shareholder Value
CBDD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CBD of Denver Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, which increases investment risk. Investing in companies on the OTC Other tier requires a high degree of due diligence and risk tolerance due to the potential for fraud, lack of liquidity, and limited information availability. These companies are not required to be SEC reporting.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Potential for fraud or manipulation.
- Lack of liquidity.
- High price volatility.
- Limited regulatory oversight.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor.
- Confirm the company's good standing with the Secretary of State.
- Company is a subsidiary of Swiss Industry Ventures AG.
- Company has been in operation since 2018.
- Company focuses on a growing market segment (CBD).
- Company has a defined business model.
- Company has a physical headquarters in Centennial, Colorado.
CBD of Denver Inc. Healthcare Stock: Key Questions Answered
What does CBD of Denver Inc. do?
CBD of Denver Inc. is involved in the development, research, and distribution of premium hemp extract products. The company focuses on commercializing cannabidiol (CBD) products, catering to the growing demand for CBD-based solutions. Operating as a subsidiary of Swiss Industry Ventures AG, CBD of Denver Inc. aims to establish itself as a key player in the CBD market by focusing on product quality, innovation, and strategic distribution partnerships. The company's products are targeted towards consumers seeking wellness and potential therapeutic benefits from CBD.
What do analysts say about CBDD stock?
As of 2026-03-16, there is no available analyst coverage for CBDD stock. The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making an investment decision. The lack of analyst coverage increases the uncertainty surrounding the stock's valuation and future performance. The company's gross margin of 27.1% should be considered in any valuation analysis.
What are the main risks for CBDD?
The main risks for CBDD include intense competition in the CBD market, evolving regulations and consumer preferences, potential for negative publicity or product recalls, and fluctuations in the price of hemp extract. The company's small market capitalization and OTC listing also present significant risks. Limited financial disclosure and lack of liquidity further increase the risk of investing in CBDD. Investors should carefully evaluate these risks before considering an investment in the company.
What are the key factors to evaluate for CBDD?
CBD of Denver Inc. (CBDD) holds an AI score of 51/100 (moderate). P/E: 3.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CBDD data refresh on this page?
CBDD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBDD's recent stock price performance?
CBD of Denver Inc. (CBDD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on premium hemp extract products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBDD overvalued or undervalued right now?
CBD of Denver Inc. (CBDD) trades at 3.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBDD?
Before investing in CBD of Denver Inc. (CBDD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and disclosure status.
- AI analysis is pending for CBDD.